In several phase III clinical trials in advanced NSCLC, the combination of platinum with taxanes attained median survival times of 8 11 months and 1-year survival of 31 46%[3].
For many cancers, as overall survival has improved, the poorest patients have indeed attained the survival seen for the rich, but often only after a time lag of some 5 years or so (see Figure 4).
To calculate survival benefit it was assumed that 92% of PEG treated patients were responders and attained the survival probability of English males while 8% were non-responders and remained in PEG treatment with the survival probability of standard care (SC) patients.
CT-guided interstitial HDR-BRT attained higher survival benefits in the management of recurrent glioblastoma after initial surgery and radiotherapy with concurrent temozolomide in comparison with the other treatment modalities.
According to the current phase II trials, concomitant chemoradiotherapy is required to attain median survival time exceeding 17 months, survival rates ⩾65% at 1 year and ⩾35 % at 2 years, and ⩽50% grade 3/4 toxicity in stage III NSCLC (Gandara et al, 2001).
(1) Advanced gastric cancer exhibits poor prognosis, and even optimal combination modalities of both surgery and chemotherapy cannot attain satisfactory survival outcomes.
Of note, achievement of complete remission is not a prerequisite for attaining a survival benefit with azacitidine in higher-risk MDS.
For example, patients with the lowest BRCA1 expression, treated with cisplatin plus gemcitabine, attained a median survival of 18 months and time to progression of 11 months when Abraxas levels were low (Table S4).
Patients with high MMSET and BRCA1 attained a median survival of 36.6 months, compared with 13.9 months for those with high BRCA1 and low MMSET (P=0.003).
In contrast, with the Amaxa Nucleofector II, transfection efficiencies of up to 90%% were attained, although cell survival varied with the transfection kits and programs tested.
